Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 27;57(18):2647–2655. doi: 10.2169/internalmedicine.0793-18

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 by The Japanese Society of Internal Medicine

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 1. — Magnetic resonance imaging findings of group I. In patient 1, a new gadolinium (Gd) -enhanced lesion was found on magnetic resonance imaging (MRI) at one month after the initiation of dimethyl fumarate (DMF) (a, b). Patient 2 experienced clinical relapse with new Gd-enhanced lesions 98 days after fingolimod cessation (c, d). Patient 3 experienced clinical relapse with new Gd-enhanced lesions 97 days after fingolimod cessation (e, f). All arrows show new lesions with Gd enhancement after fingolimod cessation (a, c, e; FLAIR, b, d, f; Gd-enhanced T1-weighted image).